Suchergebnisse - "ELLIS MATTHEW J"

PubPharm (541)

1

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination : A Phase 3 Randomized Clinical Trial

enthalten in: JAMA oncology | 2024

von Ma, C. | Suman, V. | Sanati, S. | +27

2

Pan-cancer proteogenomics characterization of tumor immunity

enthalten in: Cell | 2024

von Petralia, F. | Ma, W. | Yaron, T. | +142

3

The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer

enthalten in: Nature communications | 2024

von Amara, C. | Kami Reddy, K. | Yuntao, Y. | +21

4

Kinase inhibitor pulldown assay (KiP) for clinical proteomics

enthalten in: Clinical proteomics | 2024

von Saltzman, A. | Chan, D. | Holt, M. | +7

5

Real-world Experiences in the Transplantation of Hepatitis C-NAAT-positive Organs

enthalten in: Transplantation direct | 2023

von Steinbrink, J. | Byrns, J. | Berg, C. | +14

6

A Network Approach to Identify Biomarkers of Differential Chemotherapy Response Using Patient-Derived Xenografts of Triple-Negative Breast Cancer

enthalten in: bioRxiv.org | 2023

von Petrosyan, V. | Dobrolecki, L. | Thistlethwaite, L. | +21

7

The uncharted role of HER2 mutant alleles in breast cancer

enthalten in: Oncotarget | 2023

von Kalra, R. | Lim, B. | Ellis, M. | +1

8

Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue

enthalten in: Clinical proteomics | 2023

von Chambers, A. | Chain, D. | Sweet, S. | +5

9

Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue

enthalten in: Clinical proteomics | 2023

von Chambers, A. | Chain, D. | Sweet, S. | +5

10

BIOMARKERS FOR COMBINATION THERAPY FOR ER+ BREAST CANCER

enthalten in: Europäisches Patentamt | 2023

von ELLIS MATTHEW J | ANURAG MEENAKSHI | PEROU CHARLES M

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[55]